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ABSTRACT
CpG oligodeoxynucleotides (ODN) show promise
as immunoprotective agents and vaccine adjuv-
ants.CpG ODNtype Dwereshowntoimproveclinical
outcome in rhesus macaques challenged with
Leishmania major. These ODN have a self-
complementary core sequence and a 30 end poly(G)
track that favors G-tetrad formation leading to multi-
merization. Although multimerization appearsneces-
sary for localization to early endosomes and
signaling via Toll-like receptor 9 (TLR-9), it can result
in product polymorphisms, aggregation and precip-
itation, thereby hampering their clinical applications.
This study shows that functionalizing the poly(G)
track of D ODN with thermolytic 2-(N-formyl-N-
methyl)aminoethyl (fma) phosphate/thiophosphate
protecting groups (pro-D ODN) reduces G-tetrad
formation in solution, while allowing tetrad formation
inside the cell where the potassium concentration is
higher. Temperature-dependent cleavage of the fma
groups over time further promoted formation of
stable G-tetrads. Peripheral blood cells internalized
pro-DODNefficiently,inducinghighlevelsofIFNa,IL-
6, IFNg and IP-10 and triggering dendritic cell
maturation. Administration of pro-D35 to macaques
challenged with L.major significantly increased the
numberofantigen-specificIFNg-secretingPBMCand
reduced the severity of the skin lesions demonstrat-
ing immunoprotective activity of pro-D ODN in vivo.
This technology fosters the development of
more efficient immunotherapeutic oligonucleotide
formulations for the treatment of allergies, cancer
and infectious diseases.
INTRODUCTION
Bacterialandsyntheticoligodeoxynucleotides(ODN)containing
unmethylated CpG dinucleotides in speciﬁc sequence contexts
(CpG ODN) trigger the vertebrate immune system through the
activation of Toll-like receptor 9 [TLR-9 (1,2)]. The resulting
innate immune response limits the early spread of infectious
organisms,whilepromotingthedevelopmentofadaptiveimmun-
ity. CpG ODN show promise as vaccine adjuvants and in the
treatment of asthma, allergy, infection and cancer (1,2).
Optimal sequences for the activation of TLR-9 vary among
species (3). Human and non-human primate TLR-9 respond
to three types of synthetic CpG ODN: Type D (and A),
type K [also referred to as B (1)] and type C, which have
distinct structures and immunostimulatory activities (1,4).
Oligodeoxyribonucleotides type D and A induce human pDC
to secrete high levels of IFNa, which in turn induces mono-
cytes to mature into functionally active DC, and gdT cells
and natural killer cells to secrete IFNg (5–7). In contrast to
K or C-type CpG ODN, D-type ODN do not induce pDC
maturation, do not activate B cells directly and have reduced
pro-inﬂammatory effects (6,8). Previous studies demonstrated
that administration of ODN type D, but not K or C ODN,
improves the clinical outcome in health and immunocompro-
mised non-human primates challenged with Leishmania
major [(9,10) and D. Verthelyi, unpublished data].
Unlike K and C-type ODN, which have several CpG motifs
and phosphorothioate backbones to increase resistance to
nucleases, CpG ODN type D are characterized by having a
core sequence with a single palindromic purine-pyrimidine-
CpG-purine-pyrimidine motif ﬂanked on both sides by 3–5
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Such a structure renders the sequence ﬂexible allowing for
the formation of a stem–loop conformation and/or forming
dimers with other D-type ODN molecules (6). In addition,
D-type ODN have a 30 end poly(G) motif (6), which is known
to self-associate via Hoogsteen base-pairing to form parallel
quadruplex structures called G-tetrads (11,12). CpG ODN
type A have a similar general structure, but have poly(G)
tracts on both the 30 and 50 ends and therefore can form
parallel and anti-parallel quadruplex structures (12,13).
Recent studies show that the formation of multimers is neces-
sary for D-type ODN to localize to early transferring receptor
positive endosomes to signal through TLR-9 and induce
IFNa, and that monomeric sequences behave as competitive
antagonists (8,13,14). Indeed, disruption of the poly(G) motif
by removing them or replacing one or more guanines with
adenines or 7-deazaguanosines to impede tetrad formation
abrogates the IFNa-inducing activity (6,13,14). However,
the poly(G) motif mediated formation of tetrads poses for-
midable challenges for the synthesis, puriﬁcation, and charac-
terization of CpG ODN type D, often leading to signiﬁcant
variations between lots and hindering the clinical develop-
ment of these ODN (12,13,15). To address this issue, we have
developed a pro-drug form of CpG ODN type D (Pro-D
ODN) in which the backbone of the poly(G) track is function-
alized with 2-(N-formyl-N-methyl)aminoethyl (fma) groups.
The incorporation of these groups into ODN is achieved
during solid-phase synthesis via phosphoramidites 1a–d
[Figure 1, (16,17)]. In this study we assess the structural
and immunostimulatory characteristics of pro-D ODN and
demonstrate that they have reduced G-tetrad formation
and multimerization in solution but retain their in vitro and
in vivo immunomodulatory activity.
MATERIALS AND METHODS
Oligodeoxynucleotides
ODN D35, D144, D35 no-pal, DTP9, DTP10, K3, and
K2007, were obtained from the FDA core facility. Solid-
phase synthesis of pro-D35 and pro-D144 ODN was
performed on a scale of 1 mmol using a succinyl long chain
alkylamine controlled-pore glass (Succ-LCAA-CpG, 500 A ˚)
support functionalized with N
2-isobutyryl-50-O-DMTr-20-
deoxyguanosine as the leader nucleoside. The syntheses
were carried out using a DNA/RNA synthesizer and phos-
phoramidites 1d and/or 2a–d (Figure 1, Table 1) as 0.1 M
solutions in dry MeCN. The reaction time for each phospho-
ramidite coupling step was 180 s. The dedimethoxytritylation
step of each chain-elongation cycle was carried out over a
period of 60 s. A solution of 0.05 M 3H-1,2-benzodithiol-3-
one 1,1-dioxide in MeCN was employed as an oxidant during
the ﬁrst two chain-elongation cycles. Each of these sulfura-
tion steps was performed before the capping reaction step,
and the reaction time for these steps was 120 and 60 s, respec-
tively. By the third chain-elongation cycle, the sulfurizing
reagent was replaced with the commercial oxidizing solution
(0.02 M iodine in tetrahydrofuran/pyridine/water) and the
capping step was carried out before oxidation over a period
of 60 s. By the 18 chain-elongation cycle, the oxidant was
replaced with the sulfurizing reagent; the oxidant line was
cleaned thoroughly until it was iodine-free. Upon completion
of the DNA chain assembly, the 50-O-DMTr group was left
intact to facilitate puriﬁcation of the ODN via reversed-
phase high-performance liquid chromatography (RP-HPLC)
in both ‘trityl-on’ and ‘trityl-off’ modes.
Solid-phase synthesis of ODN fma-D35 (Table 1) was pre-
pared under conditions identical to those described above for
the preparation of pro-D35 and pro-D144 ODN with the
exception of using phosphoramidites 1a–d (18) exclusively.
Deprotection and puriﬁcation of pro-D35, pro-D144 and
fma-D35 ODN was carried out identically as described earlier
Figure 1. Deoxyribonucleoside phosphoramidites used in the solid-phase
synthesis of the oligodeoxynucleotides listed in Table 1.
Table 1. Synthetic ODN sequences used in this study
ODN Description DNA sequence
D35 CpG ODN type D (positive control) G
SG
STGCATCGATGCAGGGG
SG
SG
D144 ODN type D (GpC control) G
SG
STGCATGGATGCAGGGG
SG
SG
Pro-D35 CpG ODN type D [fma-protected 30 poly(G)] G
SG
STGCATCGATGCAG*G*G*G*G*
SG
Pro-D144 ODN type D [fma-protected 30poly(G)] G
SG
STGCATGTATGCAG*G*G*G*SG*
SG
fma-D35 fma-protected CpG ODN type D G*
SG*
ST*G*C*A*T*C*G*A*T*G*C*A*G*G*G*G*
SG*
SG
DTP9 CpG ODN type D [no 30 poly(G)] G
SG
STGCATCGATGCATGTG
ST
SG
DTP10 CpG ODN type D [no 30 poly(G) and no palindrome] G
SG
STGCATCGATATATGTG
ST
SG
D35 no-pal CpG ODN type D (no palindrome) G
SG
STGCATCGATATAGGGG
SG
SG
K2007 CpG ODN type K T
SC
SG
ST
SC
SG
ST
ST
SG
ST
SC
SG
ST
ST
ST
ST
SG
ST
SC
SG
ST
ST
K3 CpG ODN type K A
ST
SC
SG
SA
SC
ST
SC
ST
SC
SG
SA
SG
SC
SG
ST
ST
SC
ST
SC
‘S’stands for an internucleotidic phosphorothioate diester linkage; ‘*’corresponds to an internucleotidic 2-(N-formyl-N-methyl)aminoethyl phosphate triester
linkage; ‘*
S’identifies an internucleotidic 2-(N-formyl-N-methyl)aminoethyl thiophosphate triester linkage.
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an analytical 5 mm Supelcosil LC-18S column under condi-
tions described elsewhere (16).
Oligodeoxynucleotide characterization
ODN were characterized by MALDI-TOF mass spectrome-
try. Analyses were performed on an instrument operating in
delayed extraction reﬂector mode, using 3-hydroxypicolinic
acid [50 mg/ml in MeCN/H2O (1:1 v/v)] as a matrix and
ammonium citrate (50 mg/ml in H2O) as a cation exchanger.
Results are shown in Table 2.
Size exclusion (SEC)-HPLC was performed using a 5 mm
TSK-Gel G3000SWXL column (7.8 mm · 30 cm, TOSOH
Bioscience) according to the following conditions: 50 mlo f
an ODN solution (50 mM) in 30 mM sodium chloride was
injected into the column. A buffer composed of 10 mM
sodium phosphate (pH 6.9) and 300 mM sodium chloride
was then pumped, isocratically, through the column at a
ﬂow rate of 1 ml/min, over a period of 40 min. Peak heights
were normalized to the highest peak, which was set to one
arbitrary unit.
PAGE under non-denaturing conditions and circular
dichroism (CD) spectroscopy were employed to analyze the
secondary/tertiary structure of pro-D35, D35, D35 no-pal,
DTP9, DTP10 and K3 ODN. Each lyophilized ODN
(0.3–1 OD260) was dissolved in distilled water (10 ml) to
which 2 ml of loading buffer (40% sucrose and 0.25% bro-
mophenol blue) was added. The samples were loaded on a
native gel (20% polyacrylamide and 1· TBE, pH 8.3) and
were electrophoresed at 250 V until the bromophenol blue
dye had traveled 20 cm at  25 C. The gel was then stained
using stains-all and processed as described elsewhere (16).
CD analyses were performed under the following condi-
tions: (i) each lyophilized ODN was dissolved in 10 mM
Tris, pH 8.5, to a ﬁnal concentration of 50 mM; (ii) prior to
recording the CD spectrum, 50 ml of each ODN solution
was diluted further in 10 mM Tris, pH 7.5 (300 ml), or in a
solution (300 ml) of 10 mM Tris, pH 7.5, and 100 mM KCl;
(iii) CD spectra were recorded in increments of 0.5 nm
between 230 and 320 nm, with a 5 s integration time; (iv)
for each ODN CD spectrum, a baseline blank was recorded
under identical conditions and subtracted from the original
CD spectrum using the KaleidaGraph software; and (v) all
measurements were performed at 37 C in a cuvette having
a 2 mm path length.
All ODN had <0.01 EU/ml as assessed by the Limulus
amebocyte lysate assay (Cambrex, Walkersville, MD).
Isolation of cells and cell culture
Elutriated monocytes or human peripheral blood mononu-
clear cells (PBMC) were provided by the Blood Bank of
the National Institutes of Health, Bethesda, MD and separated
by density gradient centrifugation over Ficoll–Hypaque as
described elsewhere (6). Rhesus macaque PBMC were iso-
lated and processed in the same manner. Cells were cultured
at a density of 2 · 10
6 cells/ml, at 37 C in RPMI-1640 media
supplemented with 5% (ﬂow cytometry) or 10% (super-
natants) FCS and 100 U penicillin/ml, 100 mg streptomycin/
ml, glutamine, non-essential amino acids, HEPES and b-
mercaptoethanol as described earlier (9). One micromolar
concentration of each ODN was used to stimulate cytokine
production, dendritic cell maturation and activation. Cell
viability after 72 h was >95% as assessed by trypan blue
staining.
Cellular CpG ODN binding and uptake. D35, K3, and pro-
D35 ODN were labeled, each with ﬂuorescein isothiocyanate
(FITC) as described previously (19). Two million monocytes
were incubated with 3 mM CpG ODN-FITC in 1· PBS for
30 min, at 37 C. Cells were washed twice with PBS–1%
BSA–0.1% sodium azide and resuspended in 0.5 ml of ﬂow
cytometry buffer. Fluorescence was determined using a
FACSCalibur ﬂow cytometer (BD Biosciences, San Jose,
CA) (total FITC MFI value). Subsequently, surface ﬂuores-
cence was quenched by adding 0.5 ml of 1:1 trypan blue in
PBS over a period of 5 min on ice (intracellular FITC).
The percentage of internalized ODN was calculated from
the following ratio: (intracellular FITC MFI value/total
FITC MFI value) · 100.
ELISA. Cytokine production was assessed as reported earlier
(20). Brieﬂy, 96-well microtiter plates (Immunolon 2; Dynex
Inc., Chantilly,VA) were coated with anti-cytokine antibody
(Ab) and blocked with PBS–5% BSA. Supernatants from
PBMC cultures were added, and their cytokine content
quantiﬁed by the addition of biotin-labeled anti-cytokine Ab
followed by phosphatase-conjugated avidin and phosphatase-
speciﬁc colorimetric substrate. Standard curves were gener-
ated using known amounts of recombinant human cytokine.
All assays were performed in triplicate.
Table 2. Molecular weight determination of oligodeoxynucleotides by MALDI-TOF mass spectrometry
ODN Molecular formula Calcd MW (M-H)
  Exp. MW (M-H)
  Exp. mass error
a (%) Exp. MW
b (M-H)
 
D35 C197H224N85O114P19S4 6320 6322 +0.03 6319
Pro-D35 C217H278N90O119P19S4 6764 6763  0.01 6759
Pro-D144 C218H265N89O120P19S4 6769 6772 +0.04 ND
DTP9 C197H227N76O117P19S4 6248 6244  0.06 ND
DTP10 C198H229N75O117P19S4 6248 6247  0.02 ND
D35 no-pal C199H226N83O115P19S4 6337 6342 +0.08 ND
K2007 C216H255N66O121P21S21 7036 7037 +0.01 7031
K3 C193H227N68O102P19S19 6329 6327  0.03 ND
Identity of each ODN was confirmed on the basis of the concordance between its theoretical MW and its MW determined experimentally. ND, not determined.
aExperimental mass error is determined according to the following formula: (Exp. MW   Calcd MW)100/Calcd MW.
bMW was determined after four freeze/thaw cycles.
6490 Nucleic Acids Research, 2006, Vol. 34, No. 22Flow cytometry. To assess monocyte-derived DC maturation
and activation, cell cultures were stimulated with 1 mM ODN
for 48 h, then ﬁxed and analyzed by ﬂow cytometry. Staining
for cell surface markers was performed using FITC-
conjugated anti-CD14, PE-conjugated anti-CD83 and PECy5-
conjugated anti-CD86 Abs (BD/Pharmingen, San Diego,
CA). Multi-parameter ﬂow cytometry was performed accord-
ing to standard protocols (5) in a FACSCalibur ﬂow cytome-
ter. Proﬁles were gated on monocytes and 60000–250000
total events were collected. Results were analyzed using the
FlowJo software (Tree Star, Inc., OR).
Infection protocol
Rhesus macaques. Healthy 2–3 year old rhesus macaques
(Macaca mulata, four per group) were obtained from the
FDA colony in South Carolina. All studies were IACUC
approved and were conducted in an AAALAC accredited
facility. Animals were monitored daily. No changes in
weight, appetite, demeanor or skin modiﬁcations were
evident during infection or treatment. Treatments were
administered and peripheral blood samples obtained from
ketamine-anesthetized animals (10 mg/kg, Ketaject; Phoenix
Pharmaceuticals, St Joseph, MD).
Leishmania major. L.major clone VI promastigotes (MHOM/
IL/80/Friedlin) were grown as described in the literature (21).
Macaques were randomly assigned to treatment groups and
then challenged intradermally in the forehead with 1 · 10
6
parasites per site, at three sites 3 cm apart, and treated with
500 mg/kg CpG ODN (subcutaneous in the inter-scapular
space) 3 days before and 3 days after challenge, or left
untreated. Monkeys inoculated with live metacyclic pro-
mastigotes developed a typical self-limited in situ lesion
characterized by erythema, induration, and ulceration that
resolved in 8–12 weeks. Lesion size, which reﬂects the sever-
ity of infection, was measured weekly in a blinded fashion.
ELIspot. The number of PBMC secreting IFNa, IP-10 and
IFNg in response to CpG ODN or soluble Leishmania antigen
(SLA) was determined by ELIspot as described earlier (21).
Brieﬂy, Immunolon 2 96-well plates were coated overnight
at 4 C with 1 mg/ml of anti-human IFNa (PBL, Piscataway,
NJ), IFNg (Clone GZ4; Alexis, San Diego, CA) or IP-10 anti-
bodies (R & D systems, Minneapolis, MN) in PBS and then
blocked with PBS–5% BSA for 1 h. The plates were overlaid
with 0.1–2 · 10
5 cells/well in triplicates and incubated at
37 C in a humidiﬁed 5% CO2 in air incubator for 12 h
(IFNa) or 24 h (IP-10) with 1 mM of CpG ODN, or 18 h
in the presence of 25 mg/ml SLA or 10 mg/ml of ovalbumin.
After washing, 1 mg/ml of biotin-conjugated anti-human
IFNa (PBL), anti-IP-10 (R & D Systems) or anti-IFNg anti-
body (clone 76-B-1; Mabtech, Sweden) were added and
plates were incubated for 2 h, washed and subsequently over-
laid with alkaline phosphatase-conjugated streptavidin. Spots
were visualized by the addition of 5-bromo-4-chloro-3-indolyl
phosphate (Sigma, St Louis, MO)in low melt agarose (Sigma).
Statistical analysis
Differences in lesion sizes were tested by repeated-measures
ANOVA using the Proc Mixed procedure from the statistical
analysis system. One-way ANOVA was used to test differ-
ences in cytokine levels and cytokine secreting cells.
RESULTS AND DISCUSSION
Reduced G-tetrad formation of pro-CpG type D in
K
+-free media
Pro-D35 was synthesized and puriﬁed as described above
using phosphoramidite 1d, so that ﬁve internucleotidic link-
ages of the ODN poly(G) tract were functionalized with
fma groups. MALDI-TOF MS analysis of puriﬁed pro-D35
ODN (Table 2) revealed an experimental molecular weight
(MW) within 0.1% of its calculated MW, thereby conﬁrming
the ODN’s identity.
To assess the presence of ODN multimerization, K, D and
pro-D ODN were analyzed by PAGE under non-denaturing
conditions. As reported previously for CpG ODN type A
(14) several bands were observed for D35 ODN, indicating
that poly(G) bearing ODN exist as a mixture of monomeric,
dimeric and multimeric structures (Figure 2A). The bands
corresponding to the multimerized forms of D35 vanished
when the sample was heated for 20 min at 96 C and immedi-
ately cooled on ice (data not shown). The self-complementary
motif appears to be required for the formation of dimers
as D35 no-pal showed bands corresponding to the monomer
and high-order multimer, but not dimers. Despite having the
same sequence as D35, pro-D35, similar to DTP9 which lacks
the poly(G) tract, showed a major band corresponding to the
dimeric form and a minor one corresponding to the mono-
meric form. The dimer band for pro-D35 exhibited a slower
electrophoretic mobility and a lighter staining pattern when
compared with the dimeric form of the parental D35, thereby
reﬂecting reduction of the charge/mass ratio of pro-D35
ODN. The decreased multimerization of pro-D35 was
conﬁrmed by size exclusion HPLC. As shown in Figure 2B,
pro-D35 and K ODN eluted as single peaks, whereas D35
showed additional peaks reﬂecting a mixture of monomeric
and multimeric forms.
The 30 poly(G) motif of D-type ODN is known to con-
tribute to multimerization through formation of G-tetrad
structures (13,14). CD studies showed that D35 displays a
characteristic parallel-stranded quadruplex spectrum with
maximal ellipticity at  265 nm and a minimal ellipticity
 240 nm (Figure 2C). However, as shown by the CD
spectrum of D35 no-pal, tetrad formation did not require
the dimerization of the ODN through self-complementary
far-ﬂanking regions. This spectrum was different from the
CD signature of K3 ODN or DTP9, which do not have
poly(G) sequences, and showed a maximum and minimum
ellipticity at  280 nm and  260 nm, respectively, a pattern
associated with monomeric sequences (Figure 2C). When
recorded in the presence of 100 mM KCl (a potassium con-
centration similar to that of an intracellular milieu), the CD
proﬁle of either ODN was unchanged. In contrast, pro-D35
showed a CD proﬁle similar to that of DTP9 in the absence
of KCl (maximum ellipticity at  275 nm), but displayed
one consistent with G-tetrad formation in the presence of
KCl (100 mM) (Figure 2C).
A previous study had shown that fma thiophosphate or
phosphate protecting groups are thermolytically cleaved off
the ODN with a half time of 72 h or 56 h, respectively, at
37 C (16). Our own analysis of the impact of temperature
on tetrad formation showed that D35 and K2007 ODN main-
tained their tertiary (tetrad/no tetrad) structure over time (data
Nucleic Acids Research, 2006, Vol. 34, No. 22 6491not shown). In contrast, the CD spectrum of pro-D35 ODN in
the presence of potassium at 37 C (Figure 2D) showed a pro-
gressive increase in G-quadruplex signature over a period of
72 h suggesting that with time, the formation of G-tetrads is
commensurate with the thermolytic conversion of pro-D35 to
D35. Together these data strongly suggest that pro-D ODN do
not form G-quadruplex structures in solutions low in potas-
sium salt concentrations but can form G-tetrads inside the
cell where the concentrations of potassium are higher.
Further, the G-tetrads become more stable with time as the
thermolytic moieties are cleaved.
Cellular uptake and immunostimulatory properties
of pro-D ODN
CpG ODN interact with TLR-9 within early endosomes; thus
cellular uptake must occur prior to signaling (22,23).
Although cellular uptake is CpG motif-independent, studies
have shown that poly(G) motifs increase ODN internalization
and alter their intracellular location (8,19,24,25). It was there-
fore important to assert whether changing the ODN structure
and the polarity of the poly(G) tract would interfere with
cellular uptake. Binding and internalization of FITC-labeled
ODN was assessed by ﬂow cytometry as previously reported
(19). Cellular binding of pro-D35 was 80.6 ± 2.8% that
of parental D35, but the change in polarity of the protec-
ted poly(G) sequence did not affect ODN internalization
(Figure 3). Indeed, even when all the internucleotidic
phosphate/thiophosphate linkages of D35 were protected
with fma groups (fma-D35 ODN), there was no signiﬁcant
reduction in ODN internalization suggesting that cellular
uptake of CpG ODN is independent of its polarity and of
G-tetrad formation. Furthermore, PBMC stimulated with
Figure 2. Secondary structure and multimerization: (A) ODNs (0.3–1 OD260) were analyzed by gel electrophoresis under non-denaturing conditions (20%
polyacrylamide and 1· TBE, pH 8.3) at  25 C. The gel was electrophoresed at 250 V until the bromophenol blue marker (fastest moving band marked with
black triangle) had traveled 20 cm, and was then stained with Stains-all. Electrophoretic mobility of monomeric ODN is indicated by a solid arrow, whereas the
open arrow shows the mobility of ODN exhibiting secondary structures and/or self-complementary dimerization. Controls (not shown) included: boiled D 35 and
K2007 (Table 1). Note that ODN with 30 poly(G) tracts (D35, D35 no-pal) have higher order structures that are absent when the poly(G) sequence is deleted
(DTP9 and DTP10) or protected with fma groups (pro-D35). (B) Aggregate formation assessed by size-exclusion HPLC using a TSK-gel column. Solutions of
D35, pro-D35 and K3 were prepared in 30 mM NaCl. (C) G-tetraplex formation monitored by circular dichroism (CD) spectroscopy in the presence and absence
of KCl. The presence of G-tetrad is characterized by a maximal positive ellipticity at  265 nm and a minimal negative ellipticity near 240 nm (D35 ODN). CD
units are in millidegrees. In the absence of G-tetrad (CpG ODN type K), the maximal positive and minimal negative ellipticities are shifted to  280 nm and
 260 nm, respectively. Note that the CD spectrum of pro-D35 shows the absence of G-tetrad formation in the absence of potassium salt, whereas the signature
of G-tetrad formation is detected in the presence of potassium salt. (D) Time course showing changes in the CD spectra of pro-D35 over time in the presence
of potassium salt (100 mM KCl, 37 C).
6492 Nucleic Acids Research, 2006, Vol. 34, No. 22pro-D35 in vitro for 72 h induced secretion of IFNa, IL-6,
IP-10 and IFNg to levels that were similar to those achieved
with D35 (Figure 4A). In contrast, fma-D35, despite uptake,
did not induce an increase in cytokine/chemokine levels
(data not shown). Finally, pro-D35 was as effective as D35
in inducing monocytes to mature into myeloid DC after
48 h in culture, as inferred by expression of CD83, CD86,
CD14, MHC II and CD40 (Figure 4B and data not
shown), whereas fma-D35 failed to drive DC maturation
(Figure 4B).
Recent studies suggest that the differential effect of B (also
called K) and D ODN is linked to the type of endosome they
localize to and propose that ODN that form multimers are
retained in the early and recycling endosomes while mono-
meric ODN are rapidly transferred to LAMP-1-positive late
endosomes and lysosomes (8,14). Other studies suggest it is
not size or the formation of multimers, but instead their abil-
ity to bind cells surface scavenger receptors such as CXCL16
what determines the type of signaling cascade that will ensue
stimulation (25). Regardless of the mechanism by which D
ODN trigger TLR-9 in the early endosomes, the use of ther-
molytic fma groups to reduce tetrad formation by poly(G)
bearing ODN did not signiﬁcantly impact on the ODN’s
uptake or immunomodulatory activity. This suggests that
the addition of formyl groups to the poly(G) strand does
not alter the intracellular localization or the signaling cascade
initiated by pro-D35. In contrast, placement of protective
groups on the CpG motif prevents its immunomodulatory
activity suggesting that they would interfere with the activa-
tion of TLR-9.
Figure 3. Cellular binding and uptake of pro-ODN. Binding and uptake
by elutriated monocytes were measured by flow cytometry using FITC-
labeled ODN (3 mM, 30 min at 37 C). (A) Shows similar total fluorescence
(binding and uptake) for D35 and pro-D35 (Data are representative of
five independent experiments). (B) Percent internalized ODN relative to
total fluorescence. Fluorescence of surface-bound ODN was quenched
using trypan blue staining (1:4 dilution, 10 min on ice) and calculated as
follows: (MFI of internalized fluorescence/MFI of total fluorescence) · 100.
Figure 4. Immunomodulatory effect of pro-D35 in vitro:( A) Response of human PBMC to pro-D35. IFNa, IFNg, IL-6 and IP-10 levels were quantified by
ELISA in 72 h supernatants PBMC from eight healthy donors. Note that pro-D35 and D35 induced similar cytokine levels. (B) CpG ODN type D mediated
differentiation of monocytes into mature DC. Elutriated monocytes were incubated with 1 mM ODN for 48 h. Cells were fixed and stained for expression of
CD83 and CD86. (Results are representative of five independent experiments.)
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Asian rhesus macaques (M.mulata) have been used previ-
ously to assess the activity of CpG ODN in primates, as
their immune cells respond to the same CpG ODN sequences
as human PBMC (26,27). Pro-D35 and D35 induced a sig-
niﬁcant increase in the number of cells secreting IFNa and
IP-10 upon stimulation in vitro (Figure 5A). The immunopro-
tective activity of pro-D35 was then assessed in vivo in rhesus
macaques challenged intradermally with 3 · 10
6 live L.major
metacyclic promastigotes. This animal model of cutaneous
leishmaniasis has been used previously to demonstrate the
immunoprotective effect of CpG ODNs type D (10,21).
Speciﬁcally, animals treated with D-type ODN, but not with
CpG ODN type K or type C, developed signiﬁcantly smaller
lesions than untreated animals (D. Verthelyi, unpublished
data). Twelve macaques (four/group) were treated, subcuta-
neously, in the inter-scapular space with D35 or pro-D35
ODN (0.5 mg/kg) 3 days before and after challenge or left
untreated. These macaques developed a self-limited nodular
skin lesion at the site of inoculation similar to those observed
in human cutaneous leishmaniasis (28). Animals treated with
D35 or with pro-D35 ODN around infection time developed
signiﬁcantly smaller lesion size as compared with untreated
ones (Figure 5B). The reduction in lesion size was associated
with a signiﬁcant increase in the number of antigen-speciﬁc
cells secreting IFNg early in disease progression (P < 0.05;
Figure 5C). These data demonstrate that pro-D ODN are
active and effective in vivo. Importantly, no losses of weight,
lymphadenopaties, or other adverse events were observed
during the study suggesting that these ODN do not induce
overt adverse effects at therapeutic doses.
This report is the ﬁrst to demonstrate the biological activity
of a pro-drug form of CpG ODN type D developed by incorp-
orating fma groups into the backbone of the 30 poly(G) end
(pro-D35 ODN). These protecting groups provided a transi-
tory reduction of G-tetrad formation in potassium-free solu-
tions, while allowing tetrad formation when potassium salt
concentrations mimicked those of an intracellular environ-
ment ( 100 mM). This modiﬁcation did not signiﬁcantly
affect cellular uptake or biological activity, as shown by
increased cytokine production and DC maturation, which
were comparable to that effected by the parental D35 ODN.
Finally, the clinical potential of pro-D35 ODN was demon-
strated through the signiﬁcant reduction of lesion severity
in Leishmania-infected rhesus macaques. The current ﬁndings
may have implications in other therapeutic oligonucleotides
venues, such as in anti-sense and siRNA applications, espe-
cially when the administration of these ODNs as prodrugs
may confer a therapeutic advantage.
ACKNOWLEDGEMENTS
The authors thank Dr Joao Pedras-Vasconcelos and Dr David
Davies for reviewing the manuscript. The L. major parasites
were a kind gift of Dr David Sacks, NIAID. In addition, we
thank Dr Phil Snoy, Dr Brianna Skinner-Harris, Ray Olsen and
the Animal Care Facility staff for their care of the non-human
primates included in this study. C.A. is a fellow at the
Figure 5. Immunomodulatory effect of pro-D35 in rhesus macaques. (A) Response of PBMC from healthy rhesus macaques to CpG ODN stimulation in vitro.
Three days after CpG ODN treatment, the number of IFNa and IP-10 secreting cells was assessed by ELIspot after 12 and 24 h of in vitro stimulation,
respectively. Statistical significance was determined by one-way ANOVA. (B/C) Rhesus macaques (n ¼ 4/group) were challenged with 10
6 L.major metacyclic
promastigotes (intradermally) and treated with CpG ODN (supracutaneously; 0.5 mg/kg) 3 days before and after challenge. Saline-treated macaques served as
controls. (B) IFNg-secreting PBMC in macaques challenged with L.major and re-stimulated in vitro with soluble Leishmania antigen (SLA) or unrelated protein
(ovalbumin) were determined by ELIspot at specified time points. (C) Development of cutaneous lesions in response to L.major infection and CpG ODN
treatment. Figure shows average size of the lesion calculated as: [mean diameter/2]
2 ·p . Note that the lesion size from macaques treated with D35 or pro-D35
ODN peaked earlier and were smaller (P < 0.05) than those in untreated macaques.
6494 Nucleic Acids Research, 2006, Vol. 34, No. 22Postgraduate Research Participation Program at the Center for
Drug Evaluation and Research administered by the Oak Ridge
Institute for Science and Education through an interagency
agreement between the US Department of Energy and the US
Food and Drug Administration. The assertions herein are the
private ones of the authors and are not to be construed as
official or as reflecting the views of the Food and Drug
Administration at large. Funding to pay the Open Access
publication charges was provided by the Office of
Pharmaceutical Sciences, Office of Biotechnology Products,
CDER, FDA.
Conflict of interest statement. Serge Beaucage, Andrzej
Grajkowski and Daniela Verthelyi are named as inventors
on a patent application related to these oligonucleotides.
There are no other conflicts to declare.
REFERENCES
1. Krieg,A.M. (2006) Therapeutic potential of Toll-like receptor
9 activation. Nature Rev. Drug Discov., 5, 471–484.
2. Klinman,D.M. (2004) Immunotherapeutic uses of CpG
oligodeoxynucleotides. Nature Rev. Immunol., 4, 249–258.
3. Bauer,S., Kirschning,C.J., Hacker,H., Redecke,V., Hausmann,S.,
Akira,S., Wagner,H. and Lipford,G.B. (2001) Human TLR9 confers
responsiveness to bacterial DNA via species-specific CpG motif
recognition. Proc. Natl Acad. Sci. USA, 98, 9237–9242.
4. Verthelyi,D. and Zeuner,R.A. (2003) Differential signaling by CpG
DNA in DCs and B cells: not just TLR9. Trends Immunol., 10,
519–522.
5. Gursel,M., Verthelyi,D. and Klinman,D.M. (2002) CpG
oligodeoxynucleotides induce human monocytes to mature into
functional dendritic cells. Eur. J. Immunol., 32, 2617–2622.
6. Verthelyi,D., Ishii,K.J., Gursel,M., Takeshita,F. and Klinman,D.M.
(2001) Human peripheral blood cells differentially recognize and
respond to two distinct CpG motifs. J. Immunol., 166, 2372–2377.
7. Krug,A., Rothenfusser,S., Hornung,V., Jahrsdorfer,B., Blackwell,S.,
Ballas,Z.K., Endres,S., Krieg,A.M. and Hartmann,G. (2001)
Identification of CpG oligonucleotide sequences with high induction of
IFNa/b in plasmacytoid dendritic cells. Eur. J. Immunol., 31,
2154–2163.
8. Guiducci,C., Ott,G., Chan,J.H., Damon,E., Calacsan,C., Matray,T.,
Lee,K.D., Coffman,R.L. and Barrat,F.J. (2006) Properties regulating
the nature of the plasmacytoid dendritic cell response to Toll-like
receptor 9 activation. J. Exp. Med., 203, 1999–2008.
9. Verthelyi,D., Kenney,R.T., Seder,R.A., Gam,A.A., Friedag,B. and
Klinman,D.M. (2002) CpG oligodeoxynucleotides as vaccine adjuvants
in primates. J. Immunol., 168, 1659–1663.
10. Verthelyi,D., Gursel,M., Kenney,R.T., Lifson,J.D., Shuying,L.,
Mican,J. and Klinman,D.M. (2003) CpG Oligodeoxynucleotides
protect normal and SIV infected macaques from Leishmania infection.
J. Immunol., 170, 4717–4723.
11. Panyutin,I.G., Kovalsky,O.I., Budowsky,E.I., Dickerson,R.E.,
Rikhirev,M.E. and Lipanov,A.A. (1990) G-DNA: A twice-folded DNA
structure adopted by single-stranded oligo(dG) and its implications for
telomeres. Proc. Natl Acad. Sci. USA, 87, 867–870.
12. Costa,L.T., Kerkmann,M., Hartmann,G., Endres,S., Bisch,P.M.,
Heckl,W.M. and Thalhammer,S. (2004) Structural studies of
oligonucleotides containing G-quadruplex motifs using AFM. Biochem.
Biophys. Res. Commun., 313, 1065–1072.
13. Wu,C.C.N., Lee,J., Raz,E., Corr,M. and Carson,D. (2004) Necessity of
oligonucleotide aggregation for Toll-like receptor 9 activation.
J. Biol. Chem., 279, 33071–33078.
14. Kerkmann,M., Costa,L.T., Richter,C., Rothenfusser,S., Battiany,J.,
Hornung,V., Johnson,J., Englert,S., Ketterer,T., Heckl,W. et al. (2005)
Spontaneous formation of nucleic acid-based nanoparticles is
responsible for high interferon-{alpha} induction by cpg-a
in plasmacytoid dendritic cells. J. Biol. Chem., 280, 8086–8093.
15. Marshall,J.D., Fearon,K., Abbate,C., Subramanian,S., Yee,P.,
Gregorio,J., Coffman,R.L. and Van Nest,G. (2003) Identification of
a novel CpG DNA class and motif that optimally stimulate B cell
and plasmacytoid dendritic cell functions. J. Leukoc. Biol., 73,
781–792.
16. Grajkowski,A., Pedras-Vasconcelos,J., Wang,V., Ausin,C., Hess,S.,
Verthelyi,D. and Beaucage,S.L. (2005) Thermolytic CpG-containing
DNA oligonucleotides as potential immunotherapeutic prodrugs.
Nucleic Acids Res., 33, 3550–3560.
17. Grajkowski,A., Cieslak,J., Chmielewski,M.K., Marchan,V.,
Phillips,L.R., Wilk,A. and Beaucage,S.L. (2003) Conceptual
‘heat-driven’ approach to the synthesis of DNA oligonucleotides on
microarrays. Ann. NY Acad. Sci., 1002, 1–11.
18. Grajkowski,A., Wilk,A., Chmielewski,M.K., Phillips,L.R. and
Beaucage,S.L. (2001) The 2-(N-formyl-N-methyl)aminoethyl
group as a potential phosphate/thiophosphate protecting group in
solid-phase oligodeoxyribonucleotide synthesis. Org. Lett., 3,
1287–1290.
19. Gursel,M., Verthelyi,D., Gursel,I., Ishii,K.J. and Klinman,D.M. (2002)
Differentialandcompetitiveactivationofhumanimmunecellsbydistinct
classes of CpG oligodeoxynucleotide. J. Leukoc. Biol., 71, 813–820.
20. Zeuner,R.A., Klinman,D.M., Illei,G., Yarboro,C., Ishii,K.J., Gursel,M.
and Verthelyi,D. (2003) Response of peripheral blood mononuclear
cells from lupus patients to stimulation by CpG oligodeoxynucleotides.
Rheumatology (Oxford), 42, 563–569.
21. Flynn,B., Wang,V., Sacks,D.L., Seder,R.A. and Verthelyi,D. (2005)
Prevention and treatment of cutaneous Leishmaniasis in primates by
using synthetic type D/A oligodeoxynucleotides expressing CpG
motifs. Infect. Immun., 73, 4948–4954.
22. Ahmad-Nejad,P., Hacker,H., Rutz,M., Bauer,S., Vabulas,R.M. and
Wagner,H. (2002) Bacterial CpG-DNA and lipopolysaccharides
activate Toll-like receptors at distinct cellular compartments.
Eur. J. Immunol., 32, 1958–1968.
23. Latz Schoenmeyer,A., Visintin,A., Fitzgerald,K.A., Monks,B.G.,
Knetter,C.F., Lien,E., Nilsen,N.J., Espevik,T. and Golenbock,D.T.
(2004) TLR9 signals after translocating from the ER to CpG DNA in
the lysosome. Nature Immunol., 5, 190–198.
24. Bartz,H., Mendoza,Y., Gebker,M., Fischborn,T., Heeg,K. and
Dalpke,A. (2004) Poly-guanosine strings improve cellular uptake and
stimulatory activity of phosphodiester CpG oligonucleotides in human
leukocytes. Vaccine, 23, 148–155.
25. Gursel,M., Gursel,I., Mostowski,H.S. and Klinman,D.M. (2006)
CXCL16 influences the nature and specificity of CpG-induced immune
activation. J. Immunol., 177, 1575–1580.
26. Hartmann,G., Weeratna,R.D., Ballas,Z.K., Payette,P., Blackwell,S.,
Suparto,I., Rasmussen,W.L., Waldshmidt,M., Sajuthi,D., Purcell,R.H.
et al. (2000) Delineation of a CpG phosphorothioate
oligodeoxinucleotide for activating primate immune responses in vitro
and in vivo. J. Immunol., 164, 1617–1624.
27. Verthelyi,D. and Klinman,D.M. (2003) Immunoregulatory activity of
CpG oligonucleotides in humans and nonhuman primates.
Clin. Immunol., 109, 64–71.
28. Amaral,V.F., Ransatto,V.A.O., Conceicao-Solva,F., Molinaro,E.,
Ferreira,V., Coutinho,S.G., McMahon-Pratt,D. and Grimaldi,G. (1996)
Leishmania amazonensis: The asian rhesus macaques (Macaca mulata)
as an experimental model for the study of cutaneous leishmaniasis.
Exp. Parasitol., 82, 34–44.
Nucleic Acids Research, 2006, Vol. 34, No. 22 6495